Acquired von Willebrand's syndrome

A single institution experience

Shaji K Kumar, Rajiv K. Pruthi, William L. Nichols

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Acquired von Willebrand's disease or syndrome (AVWS) is a rare bleeding disorder distinguished from congenital von Willebrand's disease by age at presentation and absence of personal and family history of bleeding disorders. We report on 22 patients with AVWS seen over 25 years. Mean age at diagnosis was 61.3 years (range 38-86 years); most patients had a spontaneous or a post-operative hemorrhage at presentation. Gastrointestinal bleeding and epistaxis were the most common spontaneous symptoms. Bleeding time was prolonged in most patients, associated with marked reductions in plasma von Willebrand factor antigen and ristocetin cofactor activity. Plasma VWF multimer distribution was normal (type 1 pattern) in 5 patients, indeterminate (no multimers detectable) in 6 patients (type 3 pattern), and abnormal (decreased higher-molecularweight multimers, type 2 pattern) in 11 patients. None of 17 patients tested had an inhibitor of ristocetin cofactor activity. An underlying malignant or benign hematologic disease was found in 18 patients, and 1 patient had Crohn's disease. Desmopressin was effective in only half the patients so treated, but all patients responded to treatment with VWF-containing concentrates. Resolution of AVWS occurred with therapy of lymphoma (1 patient) and chronic lymphocytic leukemia (1 patient). Sixteen patients were alive at last follow-up; no deaths were related to bleeding. AVWS may be more prevalent than has been appreciated; we estimate up to 0.04%. Awareness of the existence of AVWS is essential for diagnosis and appropriate management. Therapy of associated diseases may improve the bleeding disorder.

Original languageEnglish (US)
Pages (from-to)243-247
Number of pages5
JournalAmerican Journal of Hematology
Volume72
Issue number4
DOIs
StatePublished - Apr 1 2003

Fingerprint

von Willebrand Diseases
Hemorrhage
von Willebrand Factor
Deamino Arginine Vasopressin
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Epistaxis
Bleeding Time
Hematologic Diseases
Normal Distribution
B-Cell Chronic Lymphocytic Leukemia
Crohn Disease
Lymphoma
Therapeutics

Keywords

  • Acquired von Willebrand's syndrome
  • Inhibitor
  • Monoclonal gammopathy
  • Von Willebrand factor

ASJC Scopus subject areas

  • Hematology

Cite this

Acquired von Willebrand's syndrome : A single institution experience. / Kumar, Shaji K; Pruthi, Rajiv K.; Nichols, William L.

In: American Journal of Hematology, Vol. 72, No. 4, 01.04.2003, p. 243-247.

Research output: Contribution to journalArticle

Kumar, Shaji K ; Pruthi, Rajiv K. ; Nichols, William L. / Acquired von Willebrand's syndrome : A single institution experience. In: American Journal of Hematology. 2003 ; Vol. 72, No. 4. pp. 243-247.
@article{716a4ff1f6b64a78a952728afc45a3c3,
title = "Acquired von Willebrand's syndrome: A single institution experience",
abstract = "Acquired von Willebrand's disease or syndrome (AVWS) is a rare bleeding disorder distinguished from congenital von Willebrand's disease by age at presentation and absence of personal and family history of bleeding disorders. We report on 22 patients with AVWS seen over 25 years. Mean age at diagnosis was 61.3 years (range 38-86 years); most patients had a spontaneous or a post-operative hemorrhage at presentation. Gastrointestinal bleeding and epistaxis were the most common spontaneous symptoms. Bleeding time was prolonged in most patients, associated with marked reductions in plasma von Willebrand factor antigen and ristocetin cofactor activity. Plasma VWF multimer distribution was normal (type 1 pattern) in 5 patients, indeterminate (no multimers detectable) in 6 patients (type 3 pattern), and abnormal (decreased higher-molecularweight multimers, type 2 pattern) in 11 patients. None of 17 patients tested had an inhibitor of ristocetin cofactor activity. An underlying malignant or benign hematologic disease was found in 18 patients, and 1 patient had Crohn's disease. Desmopressin was effective in only half the patients so treated, but all patients responded to treatment with VWF-containing concentrates. Resolution of AVWS occurred with therapy of lymphoma (1 patient) and chronic lymphocytic leukemia (1 patient). Sixteen patients were alive at last follow-up; no deaths were related to bleeding. AVWS may be more prevalent than has been appreciated; we estimate up to 0.04{\%}. Awareness of the existence of AVWS is essential for diagnosis and appropriate management. Therapy of associated diseases may improve the bleeding disorder.",
keywords = "Acquired von Willebrand's syndrome, Inhibitor, Monoclonal gammopathy, Von Willebrand factor",
author = "Kumar, {Shaji K} and Pruthi, {Rajiv K.} and Nichols, {William L.}",
year = "2003",
month = "4",
day = "1",
doi = "10.1002/ajh.10298",
language = "English (US)",
volume = "72",
pages = "243--247",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Acquired von Willebrand's syndrome

T2 - A single institution experience

AU - Kumar, Shaji K

AU - Pruthi, Rajiv K.

AU - Nichols, William L.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Acquired von Willebrand's disease or syndrome (AVWS) is a rare bleeding disorder distinguished from congenital von Willebrand's disease by age at presentation and absence of personal and family history of bleeding disorders. We report on 22 patients with AVWS seen over 25 years. Mean age at diagnosis was 61.3 years (range 38-86 years); most patients had a spontaneous or a post-operative hemorrhage at presentation. Gastrointestinal bleeding and epistaxis were the most common spontaneous symptoms. Bleeding time was prolonged in most patients, associated with marked reductions in plasma von Willebrand factor antigen and ristocetin cofactor activity. Plasma VWF multimer distribution was normal (type 1 pattern) in 5 patients, indeterminate (no multimers detectable) in 6 patients (type 3 pattern), and abnormal (decreased higher-molecularweight multimers, type 2 pattern) in 11 patients. None of 17 patients tested had an inhibitor of ristocetin cofactor activity. An underlying malignant or benign hematologic disease was found in 18 patients, and 1 patient had Crohn's disease. Desmopressin was effective in only half the patients so treated, but all patients responded to treatment with VWF-containing concentrates. Resolution of AVWS occurred with therapy of lymphoma (1 patient) and chronic lymphocytic leukemia (1 patient). Sixteen patients were alive at last follow-up; no deaths were related to bleeding. AVWS may be more prevalent than has been appreciated; we estimate up to 0.04%. Awareness of the existence of AVWS is essential for diagnosis and appropriate management. Therapy of associated diseases may improve the bleeding disorder.

AB - Acquired von Willebrand's disease or syndrome (AVWS) is a rare bleeding disorder distinguished from congenital von Willebrand's disease by age at presentation and absence of personal and family history of bleeding disorders. We report on 22 patients with AVWS seen over 25 years. Mean age at diagnosis was 61.3 years (range 38-86 years); most patients had a spontaneous or a post-operative hemorrhage at presentation. Gastrointestinal bleeding and epistaxis were the most common spontaneous symptoms. Bleeding time was prolonged in most patients, associated with marked reductions in plasma von Willebrand factor antigen and ristocetin cofactor activity. Plasma VWF multimer distribution was normal (type 1 pattern) in 5 patients, indeterminate (no multimers detectable) in 6 patients (type 3 pattern), and abnormal (decreased higher-molecularweight multimers, type 2 pattern) in 11 patients. None of 17 patients tested had an inhibitor of ristocetin cofactor activity. An underlying malignant or benign hematologic disease was found in 18 patients, and 1 patient had Crohn's disease. Desmopressin was effective in only half the patients so treated, but all patients responded to treatment with VWF-containing concentrates. Resolution of AVWS occurred with therapy of lymphoma (1 patient) and chronic lymphocytic leukemia (1 patient). Sixteen patients were alive at last follow-up; no deaths were related to bleeding. AVWS may be more prevalent than has been appreciated; we estimate up to 0.04%. Awareness of the existence of AVWS is essential for diagnosis and appropriate management. Therapy of associated diseases may improve the bleeding disorder.

KW - Acquired von Willebrand's syndrome

KW - Inhibitor

KW - Monoclonal gammopathy

KW - Von Willebrand factor

UR - http://www.scopus.com/inward/record.url?scp=0037380241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037380241&partnerID=8YFLogxK

U2 - 10.1002/ajh.10298

DO - 10.1002/ajh.10298

M3 - Article

VL - 72

SP - 243

EP - 247

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -